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Abstract
Background: The incidence of central nervous system (CNS) metastases in breast cancer patients is rising and has
become a major clinical challenge. Only few data are published concerning risk factors for the development of CNS
metastases as a first site of metastatic disease in breast cancer patients. Moreover, the incidence of CNS metastases
after modern neoadjuvant treatment is not clear.
Methods: We analyzed clinical factors associated with the occurrence of CNS metastases as the first site of metastatic
disease in breast cancer patients after neoadjuvant treatment in the trials GeparQuinto and GeparSixto (n = 3160)
where patients received targeted treatment in addition to taxane and anthracycline-based chemotherapy.
Results: After a median follow-up of 61months, 108 (3%) of a total of 3160 patients developed CNS metastases as the
first site of recurrence and 411 (13%) patients had metastatic disease outside the CNS. Thirty-six patients (1%) developed
both CNS metastases and other distant metastases as the first site of metastatic disease. Regarding subtypes of the
primary tumor, 1% of luminal A-like (11/954), 2% of luminal B-like (7/381), 4% of HER2-positive (34/809), and 6% of
triple-negative patients (56/1008) developed CNS metastases as the first site of metastatic disease.
In multivariate analysis, risk factors for the development of CNS metastases were larger tumor size (cT3–4; HR 1.63, 95% CI
1.08–2.46, p = 0.021), node-positive disease (HR 2.57, 95% CI 1.64–4.04, p< 0.001), no pCR after neoadjuvant chemotherapy
(HR 2.29, 95% CI 1.32–3.97, p = 0.003), and HER2-positive (HR 3.80, 95% CI 1.89–7.64, p< 0.001) or triple-negative subtype
(HR 6.38, 95% CI 3.28–12.44, p < 0.001).
Conclusions: Especially patients with HER2-positive and triple-negative tumors are at risk of developing CNS metastases
despite effective systemic treatment. A better understanding of the underlying mechanisms is required in order to
develop potential preventive strategies.
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Background
Central nervous system (CNS) metastases in breast
cancer patients are a clinically relevant problem. CNS me-
tastases are associated with shorter survival and impaired
quality of life compared with extracranial metastases.
Despite the use of neurosurgery and radiotherapy, only
the minority of patients survives longer than 1 year [1].
Depending on tumor subtype, survival times of
3.7–15 months after the occurrence of CNS metas-
tases have been described [2]. As in the primary tumor
setting, patients with triple-negative breast cancer (TNBC)
have the worst prognosis. In a retrospective study by
Niikura et al. with 1256 patients diagnosed with brain
metastases, the median overall survival of TNBC
patients after the CNS metastasis diagnosis was 4.9months
and that of human epidermal growth factor receptor 2
(HER2)-positive patients was 11.5months [3]
In the treatment of non-metastatic breast cancer, rele-
vant improvement has been achieved in the last years
resulting in prolonged survival. Neoadjuvant systemic
treatment has become a standard procedure for the
treatment of primary breast cancer. Pathologic complete
response (pCR) rates after neoadjuvant chemotherapy
are increasing with current treatment standards and are
reflected by an improved patient outcome. pCR rates of
58% for HER2 positive and 37% for TNBC could be
achieved [4]. A 5-year breast cancer-specific survival rate of
96% and 75% was observed in an analysis of Boughey et al.
for HER2-positive and TNBC patients, respectively [5].
However, about 4% of HER2-positive and 7% of TNBC
patients develop CNS metastases after the adjuvant treat-
ment (5-year cumulative incidence of CNS metastases) in
historic cohorts [6], and it remains unclear which patients
are at high risk for the development of CNS metastases
after neoadjuvant treatment with the current standard.
So far, limited insight is available into the biology of
CNS metastases in breast cancer patients. It could be as-
sumed that patients who develop CNS metastases as a
first site of metastatic disease have distinct clinical or
tumor features and that these might help to better
understand factors that are a predisposition for CNS
metastases. However, only limited studies are published
concerning risk factors for the development of CNS me-
tastases. Moreover, most studies on this topic evaluated
cohorts with only a small number of patients that did
not receive treatment regimens as of the current stan-
dard. This is of relevance since modern targeted therapy
could potentially influence the pattern of metastatic
spread. We therefore investigated the clinical factors
associated with the occurrence of CNS metastases as the
first site of metastatic disease in 3160 breast cancer
patients after modern neoadjuvant systemic therapy.
The preliminary results of our evaluation were presented
at the San Antonio Breast Cancer Symposium in 2017 [7].
Methods
The clinical data for the analysis were derived from the
neoadjuvant trials GeparQuinto and GeparSixto of the
German Breast Group, consisting of 3160 patients, who
have been treated with neoadjuvant therapy for early
breast cancer.
Briefly, in GeparQuinto, patients with primary HER2-
positive breast cancer (n = 615) received either lapatinib
or trastuzumab in addition to an anthracycline and
taxane-based therapy, patients with HER2-negative breast
cancer (n = 1925) received an anthracycline and taxane-
containing regimen and were randomly assigned to re-
ceive bevacizumab (n = 956), and those not responding
after four cycles of anthracyclines (n= 395) received pacli-
taxel (n= 198) or paclitaxel plus everolimus (n= 197) [8–10].
In GeparSixto, patients with previously untreated,
non-metastatic, TNBC (n = 315) and HER2-positive
(n = 273) breast cancer were treated with paclitaxel
and non-pegylated liposomal doxorubicin. Patients with
triple-negative breast cancer received simultaneous beva-
cizumab. Patients with HER2-positive disease received
simultaneous trastuzumab and lapatinib. Patients were
randomly assigned to receive, at the same time as the back-
bone regimens, either carboplatin or no carboplatin [11].
Written informed consent was obtained from all
patients before enrolment in the GeparQuinto and
GeparSixto trials.
Statistics
The primary objective of our analysis was to assess the
influence of the baseline characteristics and pCR on the
occurrence of CNS metastases as the first site of meta-
static disease (with or without simultaneous occurrence of
other metastases) in both trials mentioned above. It was
done by assessing time (in months, from randomization in
the study) to the occurrence of the CNS metastasis as the
first site of metastatic disease according to the competing
risk model of Fine and Gray [12], and cumulative in-
cidence function was presented graphically; other distant
metastases, contralateral breast cancer, secondary ma-
lignancies, or death before any event were considered
competing events.
The following covariates were included into a Fine-Gray
model: age in years (continuous), tumor stage (cT1–2 vs.
cT3–4), nodal status (cN0 vs. cN+), primary tumor sub-
type (TNBC, HER2 positive/negative, luminal (hormone
receptor-positive, HER2-negative) A-like (grades 1–2) and
B-like (grade 3)), and study (to adjust for possible hetero-
geneity). Additionally, a multivariate Fine-Gray model
including covariates above and pCR was performed to
explore what portion of the effect is mediated by pCR; to
avoid guarantee-time bias [13], a landmark of 24 weeks for
GeparQuinto patients and 18 weeks for GeparSixto
patients was used.
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Secondary endpoints were as follows:
 To assess time (in months, from randomization in
the study) to the occurrence of the non-CNS
metastasis as the first site of relapse (and to compare
to the time to occurrence of the CNS metastases as
the first site of metastatic disease). CNS metastases,
contralateral breast cancer, secondary malignancies,
or death before any event were considered competing
events. The cumulative incidence functions for CNS
and non-CNS metastases were presented graphically.
 To describe the first metastatic site at the first
distant relapse. The data concerning the first
metastatic site was collected in the context of
follow-up investigations.
The following categories were assessed:
 If a patient had CNS metastasis as a first event (yes/
no), if CNS metastases were the only localization
(yes/no), or if CNS metastases were diagnosed
simultaneously with other metastases (skin, bone,
liver, lung/pleura, non-locoregional lymph node, or
other localization)
 If a patient had non-CNS metastases as a first event.
The following categories of the metastasis
localization could be documented: skin, bone, liver,
lung/pleura, non-locoregional lymph node, or other
localization
The statistical analyses were performed with SAS 9.2




A total of 3160 patients treated in GeparQuinto and
GeparSixto trials were available for the analysis. Two
thousand five hundred seventy-two patients were treated
within the GeparQuinto, and 588 within the GeparSixto
trial. Seventy-three percent (n = 2306) of the patients
had a cT1 tumor stage before neoadjuvant chemotherapy.
Fifty-one percent (n = 1581) had a node-negative, and 49%
(n = 1533) a node-positive (cN1-3) primary breast cancer.
Concerning the tumor subtype, 32% (n = 1008) had a
TNBC, 30% (n = 954) a luminal A-like, 12% (n = 381) a
luminal B-like, and 26% (n = 809) HER2-positive tumor.
pCR after neoadjuvant treatment was observed in 23%
(n = 738) of the patients. The highest pCR rate was ob-
served in patients withTNBC (38%, n = 379). Patients with
HER2-positive tumors had a pCR rate of 30% (n = 245),
and luminal A- and B-like breast cancer patients had pCR
rates of 6% (n = 61) and 14% (n = 52), respectively
(Table 1).
Development of metastases (CNS metastases and non-
CNS metastases)
After a median follow-up of 61 months (IQR 45–73),
108 (3%) of a total of 3160 patients developed CNS
metastases as the first site of metastatic disease, 411
(13%) patients had distant metastases outside the brain
as the first site of metastatic disease, and 2641 (84%) of
the patients had no metastatic disease (Fig. 1: cumulative
incidence of metastases). A total of 72 patients (2%) had
CNS metastases as the only localization of the metastatic
disease, and 36 patients (1%) had other distant metas-
tases in addition to CNS metastases.
CNS metastases as the first site of metastatic disease
occurred less frequently than other metastases (5-year
cumulative incidence of CNS metastases was 3.8%, and
cumulative incidence of the metastases outside the brain
was 14.6% according to the competing risk model, Fig. 1:
cumulative incidence of metastases).
The median age of patients with CNS metastases as
the first site of metastatic disease was 49 years (range
27–75). Seventy-nine percent of the patients (n = 85)
were initially treated within GeparQuinto, and 21%
(n = 23) within the GeparSixto study.
Of the patients with CNS metastases as the first site of
metastatic disease, 57% (n = 61) had a cT1-2 tumor at
the time of diagnosis, 73% (n = 79) node-positive disease
(cN1–cN3), and 62% high grading (n = 67, G3 tumor) of
the primary tumor. After neoadjuvant therapy, most of
the patients had no pCR (n = 92, 85%).
Regarding subtypes of the primary tumor, 32% of the
patients had HER2-positive (n = 34) and 52% (n = 56)
TNBC subtype.
Patients with non-CNS metastases as the first site of
metastatic disease had a median age of 48 years (range
21–76). Eighty-six percent of the patients (n = 352) were
initially treated within GeparQuinto, and 14% (n = 59)
within the GeparSixto study.
Sixty-three percent (n = 259) of the patients with
non-CNS metastases as the first site of metastatic disease
had a cT1–2 tumor at the time of diagnosis, 60% of the
patients had node-positive disease (cN1–cN3, n = 244),
and 52% had a high-grade tumor (n = 213 with a G3
tumor). Ninety-two percent of the patients in this
group had no pCR after the neoadjuvant chemotherapy








Luminal A-like 893 (93.6) 61 (6.4)
Luminal B-like 329 (86.4) 52 (13.6)
HER2 positive 564 (69.7) 245 (30.3)
TNBC 629 (62.4) 379 (37.6)
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(n = 376). Regarding subtypes of the primary tumor,
19% of the patients in this group had HER2-positive
(n = 76) and 40% (n = 165) TNBC subtype.
Concerning the site of the first metastatic disease
(non-CNS metastases), of the 411 patients, 173 (42%)
developed bone metastases, 157 (38%) developed liver
metastases, 141 (34%) had lung/pleural metastases, 70
(17%) had lymphatic metastases in non-locoregional
lymph nodes, and 39 (9%) developed skin metastases.
Forty of 411 patients (10%) had other sites of the first
metastatic disease (non-CNS metastases).
For the detailed summary concerning patient’s charac-
teristics, see Table 2.
Factors associated with the occurrence of CNS metastases
as the first site of metastatic disease
In univariate analysis, larger tumor size, node-positive
disease, negative hormone receptor status (both estrogen
and progesterone negative), poor tumor differentiation
(G3 tumor, high Ki67), HER2-positive or triple-negative
tumor subtype, and no pCR after neoadjuvant chemo-
therapy were significantly associated with the occurrence
of CNS metastases as the first site of metastatic disease.
Thus, the 5-year cumulative incidence for the occur-
rence of CNS metastases was 5.92% for patients with a
larger initial tumor size (cT3–4) compared to 3.07% for
patients with a smaller initial tumor size (cT1–2) (hazard
ratio (HR) 2.19, 95% confidence interval (CI) 1.50–3.22,
p < 0.0001). Patients with a node-positive disease had a
5-year cumulative incidence for the occurrence of CNS
metastases of 5.74%. The risk of node-negative patients
was 2.07% (HR 3.05, CI 1.98–4.71, p < 0.0001). Con-
cerning tumor subtype, a 5-year cumulative incidence
for CNS metastases was 4.77% in HER2-positive
patients and 6.27% in triple-negative patients. Thus,
HER2 positivity was associated with a fourfold and
triple negativity with a fivefold higher risk for CNS
metastases (HR 4.1, CI 2.06–8.12, p < 0.0001 and HR
5.43, CI 2.81–10.47, p < 0.0001) compared to luminal
A-like tumor subtype.
We additionally evaluated the incidence of CNS metasta-
ses among patients with HER2-positive hormone receptor-
positive and HER2-positive hormone receptor-negative
patients. No significant difference concerning the inci-
dence of CNS metastases could be shown in our cohort
of patients between these groups of patients (HR 0.8,
95% CI 0.5–1.22, p = 0.268).
The 5-year cumulative risk for development of CNS
metastases in patients without achieving a pCR after
neoadjuvant chemotherapy was 4.18% vs. 2.49% for
patients with a pCR (HR 1.85, CI 1.06–3.24, p = 0.0316).
The BRCA status did not show a statistically signifi-
cant association with the occurrence of CNS metastases
as the first site of metastatic disease in our cohort. The
data was available for a total of 36 of 108 patients with
brain metastases (n = 9 BRCA positive, n = 27 BRCA
negative). Of these patients with known BRCA status,
those with a positive BRCA status had a 5-year CNS
metastasis incidence rate of 7.84% compared to 4.68% by
patients with a negative BRCA status (HR 1.67, 95% CI
0.78–3.57, p = 0.189).
In multivariate analysis, risk factors for the develop-
ment of CNS metastases were larger tumor size (cT3–4;
HR 1.63, 95% CI 1.08–2.46, p = 0.021), node-positive
disease (HR 2.57, 95% CI 1.64–4.04, p < 0.001), no pCR
after neoadjuvant chemotherapy (HR 2.29, 95% CI 1.32–
3.97, p = 0.003), and HER2-positive (HR 3.80, 95% CI
1.89–7.64, p < 0.001) or triple-negative subtype (HR 6.38,
95% CI 3.28–12.44, p < 0.001) (Table 3: multivariate ana-
lysis of time to CNS metastases adjusted for non-CNS
metastases as competing risk). A multivariate analysis
without consideration of pCR status did not show essen-
tially different results.
We additionally analyzed the incidence of CNS metas-
tases (relating to subtype) among patients without a
pCR. A 5-year cumulative CNS metastasis incidence rate
in the cohort of patients without a pCR was 1.3% for
luminal A-like subtype, 2.53% for luminal B-like, 5% for
HER2-positive, and 8.46% for triple-negative patients.
The risk of development of the CNS metastases as the
Fig. 1 Cumulative incidence of metastases
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first site of metastatic disease was statistically higher in
patients with HER2-positive breast cancer as well as
for triple-negative patients (HR 3.66, 95% CI 1.78–7.55,
p = 0.0004 and HR 6.50, 95% CI 3.32–12.71, p < 0.0001)
compared to patients with luminal A-like breast cancer.
In the cohort of patients with pCR, the median sur-
vival was not achieved to the time of evaluation. The
5-year cumulative incidence rates for the patients with
pCR after the neoadjuvant chemotherapy were 2.4% for
CNS metastases and 5.7% for non-CNS metastases.
Discussion
CNS metastases have become a major challenge in the
management of patients with metastatic breast cancer,
as the occurrence of CNS metastases is associated with a
particularly bad prognosis. The incidence of CNS metas-
tases in patients that have received neoadjuvant treat-
ment according to current standards has not been
reported so far. Only a few reports have examined risk
factors for the development of CNS metastases as the
first site of metastatic disease in breast cancer patients.
Identification of risk factors for developing CNS
metastases would identify a patient group that might
benefit from preventive management strategies of CNS
metastases, e.g., cranial irradiation or CNS metastasis
screening, e.g., by means of magnetic resonance imaging.
Both options are not part of the management of patients
with breast cancer in clinical routine today. However,
Table 2 Patient’s characteristics
Parameter CNS metastases as the first site
of metastatic disease, N = 108
Non-CNS metastases as the first
site of metastatic disease, N = 411
Patients without distant
relapse, N = 2641
Overall,
N = 3160
Age, median (years) 48.5 48.0 49.0 48.0
cT (n, %)
cT1–2 61 (57.0) 259 (63.2) 1986 (75.5) 2306 (73.3)
cT3 15 (14.0) 77 (18.8) 366 (13.9) 458 (14.5)
cT4a–c 5 (4.7) 26 (6.3) 118 (4.5) 149 (4.7)
cT4d 26 (24.3) 48 (11.7) 161 (6.1) 235 (7.5)
Missing 1 1 10 12
cN (n, %)
cN0 28 (26.2) 159 (39.5) 1394 (53.5) 1581 (50.8)
cN1 68 (63.6) 209 (51.9) 1100 (42.2) 1377 (44.2)
cN2 9 (8.4) 23 (5.7) 90 (3.5) 122 (3.9)
cN3 2 (1.9) 12 (3.0) 20 (0.8) 34 (1.1)
Missing 1 8 37 46
Breast cancer subtype
Luminal A-like (grades 1–2) 11 (10.2) 107 (26.2) 836 (31.7) 954 (30.3)
Luminal B-like (grade 3) 7 (6.5) 61 (14.9) 313 (11.9) 381 (12.1)
HER2+ 34 (31.5) 76 (18.6) 699 (26.5) 809 (25.7)
TNBC 56 (51.9) 165 (40.3) 787 (29.9) 1008 (32.0)
Missing 0 2 6 8
Ki67 index (n, %)
≤ 20% 10 (18.5) 58 (28.9) 438 (33.0) 506 (32.0)
> 20% 44 (81.5) 143 (71.1) 888 (67.0) 1075 (68.0)
Missing 54 210 1315 1579
Grade (n, %)
G1 0 (0.0) 10 (2.4) 88 (3.3) 98 (3.1)
G2 41 (38.0) 186 (45.5) 1305 (49.6) 1532 (48.7)
G3 67 (62.0) 213 (52.1) 1236 (47.0) 1516 (48.2)
Missing 0 2 12 14
pCR
No 92 (85.2) 376 (91.5) 1954 (74.0) 2422 (76.6)
Yes 16 (14.8) 35 (8.5) 687 (26.0) 738 (23.4)
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the low incidence of CNS metastases as the first meta-
static site observed in our cohort and the retrospective
design of the study would not justify a screening
approach during follow-up. The development of a
calculator for the risk assessment could be an aim of the
further evaluation of the collected data. On the basis of
our analysis, we can recommend to take particular
account into neurological complaints of patients with until
now not metastasized breast cancer with initially large
tumor size, node-positive disease, no-pCR status after
systemic therapy, and HER2-positive or triple-negative
tumor biology. We suggest carrying out clinical studies
investigating the role of screening options (e.g., brain
magnetic resonance imaging) for metastatic breast
cancer patients who are at high risk for developing
CNS metastases.
In our cohort of patients after neoadjuvant chemothe-
rapy, 16% of patients developed metastatic disease after a
median follow-up of 5 years. Three percent of patients
developed CNS metastases as the first metastatic site.
Factors significantly associated with the occurrence of
CNS metastases as the first site of metastatic disease were
higher tumor stage before therapy (cT3–4), node-positive
disease, HER2-positive or triple-negative subtype, and no
pCR after neoadjuvant chemotherapy. We could show
that tumor subtype remained the highest risk factor for
CNS metastases. Our results are predominantly in line
with already published analyses of smaller patient cohorts
not receiving current treatment regimens.
Gonzales-Angulo et al. [14] determined the incidence
of CNS metastases and examined associated disease
characteristics in patients with locally advanced breast
cancer or inflammatory breast cancer after a neoadjuvant
systemic therapy. Five percent of patients (38/768
patients) developed CNS metastases as the first site
of metastatic disease. Negative hormone receptor status,
nuclear grade 3, positive nodal status, and higher stage of
disease were significantly associated with the time to CNS
metastasis in this patient cohort.
Other researchers evaluated, in contrary to our design,
patient cohorts with either adjuvant systemic treatment
or mixed patient cohorts with adjuvant and neoadjuvant
approach. Thus, Dawood et al. showed an association of
CNS metastases as the first site of metastatic disease
and higher breast cancer stage for patients with initially
non-metastatic triple-negative breast cancer (n = 115)
[15]. Patients in this cohort received either adjuvant or
neoadjuvant systemic treatment. Atahan et al. observed
a correlation between CNS metastases as the first site of
metastatic disease and the initial size of the primary
tumor and nodal status in 32 patients. These patients
received an adjuvant chemotherapy [16].
A different probability of breast cancer subtypes to
metastasize into the brain was also described by others
[17–20]. Soni et al. and Kennecke et al. detected an
association between HER2-positive and TNBC subtype
and the development of CNS metastases. Martin et al.
evaluated 968 patients with brain metastases at the time
of diagnosis of breast cancer and detected that incidence
proportions were highest among patients with hormone
receptor-negative HER2-positive and triple-negative
subtypes [21]. Sihto et al. [19] and Smid et al. [20]
showed an association between basal-type cancer and
CNS metastases. Lin et al. detected that triple-negative







Analysis without consideration of pCR rate
Age (continuous) 1.001 0.984–1.018 p = 0.9359
Tumor size (cT3–4) (reference category: cT1–2) 1.830 1.223–2.737 p = 0.0033
Node-positive disease (reference category: node-negative disease) 2.681 1.710–4.205 p < 0.0001
Luminal B-like subtype (reference category: luminal A-like subtype) 1.573 0.611–4.053 p = 0.3478
HER2-positive subtype (reference category: luminal A-like subtype) 3.357 1.673–6.736 p = 0.0007
Triple-negative subtype (reference category: luminal A-like subtype) 5.569 2.882–10.758 p < 0.0001
Analysis with consideration of pCR rate
Age (continuous) 0.999 0.981–1.016 p = 0.8813
Tumor size (cT3–4) (reference category: cT1–2) 1.626 1.075–2.458 p = 0.0213
Node-positive disease (reference category: node-negative disease) 2.574 1.641–4.037 p < 0.0001
Luminal B-like subtype (reference category: luminal A-like subtype) 1.617 0.627–4.171 p = 0.3200
HER2-positive subtype (reference category: luminal A-like subtype) 3.804 1.894–7.639 p = 0.0002
Triple-negative subtype (reference category: luminal A-like subtype) 6.384 3.277–12.440 p < 0.0001
No pCR after neoadjuvant chemotherapy (reference category: pCR
after neoadjuvant chemotherapy)
2.294 1.324–3.973 p = 0.0031
Laakmann et al. Breast Cancer Research           (2019) 21:60 Page 6 of 8
tumors were associated with a greater risk of brain me-
tastases relative to hormone receptor-positive/HER2-ne-
gative tumors [22]. Vaz-Luis et al. evaluated 3394
patients with HER2-positive breast cancer and could
show that hormone receptor-negative HER2-positive
patients were more likely to have recurrence in the brain
compared to hormone receptor-positive HER2-positive
patients [23].
A noteworthy finding in our study relates to pCR rates in
the analyzed subgroups. The pCR rate in patients with
CNS metastases as the first site of metastatic disease was
higher (15%) compared to patients with other distant
metastases as the first site of metastatic disease (9%). Thus,
a good response rate to a systemic treatment seems not to
have a deciding role in the prevention of CNS metastases.
Possibly, more aggressive disseminated tumor cells, which
also did not respond to a systemic treatment, gain a
propensity to overcome the blood-brain barrier and survive
in the central nervous system. Most systemic treatment
approaches are assumed not to cross the intact blood-brain
barrier; this fact might explain why tumor cells that already
reached the CNS cannot be affected. Probably, the initially
more aggressive tumor is also a significant risk factor in the
development of CNS metastases. In our cohort, 16 patients
developed CNS metastases as the first site of metastatic
disease despite achieving a pCR. All of them had either
HER2-positive (n = 9) or TNBC (n = 7) primary tumor.
The strength of our analysis is a large cohort of patients
who received up-to-date treatment with anthracyclines
and taxanes as well as up-to-date HER2-directed therapy.
However, given the relatively low incidence of CNS metas-
tases, we cannot identify differences between the inci-
dence of CNS metastases in different treatment groups of
the trials, e.g., between lapatinib- and trastuzumab-treated
patients with HER2-positive breast cancer or in the cohort
of triple-negative patients with carboplatin therapy com-
pared to patients without carboplatin therapy. A small
number of patients with an available BRCA status in our
cohort also do not allow a confident statistical statement
concerning the correlation with the development of CNS
metastases and may be regarded solely as trend. A further
limitation of our analysis is that the incidence of CNS
metastases after the occurrence of metastatic disease was
not documented, as in many other trials. This point must
be taken into consideration by the interpretation of Fig. 1.
The flattening of the curve after 24 months does not
prove that CNS metastases do not appear after this
period of time as the curve does not include patients
that developed CNS metastases after diagnosis of
other distant metastases.
Conclusions
In conclusion, our analysis showed that especially patients
with HER2-positive and triple-negative tumors are at risk
of developing CNS metastases despite active systemic
treatment, especially when no pCR was reached. However,
also patients with pCR are at risk of developing CNS
metastases. A better understanding of the underlying
mechanisms is required in order to develop potential
preventive strategies and should help to identify molecular
mechanisms of resistance to modern therapies and clonal
selection of tumor cells with special brain tropism. Further
studies should aim to identify a group of patients that
might have a benefit of screening for brain metastases.
Further research on biomarkers for CNS metastasis de-
velopment should be performed. A translational research
project in our cohort is ongoing.
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